Osteopontin - A new marker in neoplastic diseases;Osteopontyna - Nowy marker w chorobach nowotworowych

Wspolczesna Onkologia

Volumn 12, Issue 8, 2008, Pages 349-353

  Mrochem, Jolanta ^a   Bartnik, Wieława ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Osteopontin; Progression of cancer

Indexed keywords

OSTEOPONTIN;

ARTICLE; ATHEROSCLEROSIS; BONE REMODELING; BONE STRUCTURE; CANCER GROWTH; DISEASE MARKER; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; INFLAMMATION; KIDNEY DISEASE; NEOPLASM; OSTEOBLAST; PROGNOSIS;

EID: 67149103810     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Senger DR, Wirth DF, Hynes RO. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979; 16: 885-93.
2. Ross FP, Chappel J, Alvarez JI, et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem 1993; 268: 9901-07.
3. Oldberg A, Franzen A, Heinegård D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 1986; 83: 8819-23.
4. O'Regan A, Berman JS, Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000; 81: 373-90.
5. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11: 279-303.
6. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001; 28: 1552: 61-85.
7. Senger DR, Perruzzi CA, Papadopoulos A, Tenen DG. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta 1989; 996: 43-8.
8. O'Regan AW, Chupp GL, Lowry JA, Goetschkes M, Mulligan N, Berman JS. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol 1999; 162: 1024-31.
9. Ashkar S, Weber GF, Panoutsakopoulou V, Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-64.
10. Rózański W, Klimek L, Jakubowski K, Miekoś E, Górkiewicz Z. Niekrystaliczne składniki kamieni moczowych. Urol Pol 2003; 56: 1.
11. Xanthou G, Alissafi T, Semitekolou M, et al. Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nat Med 2007; 13: 570-78.
12. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 1994; 94: 1597-1604.
13. Wai PY, Kuo PC. The role of Osteopontin in tumor metastasis. J Surg Res 2004; 121: 228-41.
14. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006; 17: 463-74.
15. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006; 6: 819-30.
16. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10 (1 Pt 1): 184-90.
17. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060-6.
18. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62: 3417-27.
19. Allan AL, George R, Vantyghem SA, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 2006; 169: 233-46.
20. Bramwell VH, Doig GS, Tuck AB, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006; 12 (11 Pt 1): 3337-43.
21. Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 2007; 14: 3419-27.
22. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002; 95: 506-12.
23. Cho H, Hong SW, Oh YJ, et al. Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 2008; 134: 909-17.
24. Radzikowski C, Opolski A, Wietrzyk J. Postepy w badaniach procesu wzrostu inwazyjnego i przerzutowania. Nowotwory 2002; 52 (Supl. 30): 56-65.
25. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with basement membrane. Annu Rev Biochem 1986; 55: 1037-57.
26. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007; 67: 330-40.
27. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008; 68: 152-61.
28. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007; 26: 6361-71.
29. Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA, Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 2007; 133: 643-52.
30. Hu Z, Lin D, Yuan J, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005; 11: 4646-52.
31. Wu CY, Wu MS, Chiang EP, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 2007; 56: 782-89.
32. Tang H, Wang J, Bai F, et al. Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochem Cell Biol 2007; 85: 103-10.
33. Rangel J, Nosrati M, Torabian S, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer 2008; 112: 144-50.
34. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007; 57: 373-80.
35. Dai N, Bao Q, Lu A, Li J. Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology 2007; 72: 89-92.
36. Schorge JO, Drake RD, Lee H, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004; 10: 3474-78.
37. Le QT, Sutphin PD, Raychaudhuri S. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003; 9: 59-67.
38. Nordsmark M, Eriksen JG, Gebski V, Alsner J, Horsman MR, Overgaard J Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 2007; 83: 389-97.
39. Le QT, Kong C, Lavori PW. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2007; 69: 167-75.
40. Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, Shimono M. Osteopontin as biomarker in early invasion by squamous cell carcinoma in tonque. J Oral Pathol Med 2007; 36: 30-4.
41. Petrik D, Lavori PW, Cao H. Plasma osteopontin is an independent prognostic marker for head and neck cancer. J Clin Oncol 2006; 33: 5291-97.
42. Eto M, Kodama S, Nomi N, Uemura N, Suzuki M. Clinical significance of elevated osteopontin levels in head and neck cancer patients. Auris Nasus Larynx 2007; 34: 343-46.
43. Donati V, Boldrini L, Dell'Omodarme M. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005; 11: 6459-65.
44. Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, Ke Y. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006; 118: 2255-61.
45. Visintin I, Feng Z, Longton G. Diagnostic marker for early detection of ovarian cancer. Clin Cancer Res 2008; 14: 1065-71.
46. Mor G, Visintin I, Lai Y. Serum protein markers for early detection of ovarian cancer. PNAS 2005; 102: 21: 7677-82.
47. Kim JH, Skates SJ, Uede T. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-79.
48. Mrochem J, Sodowski K, Deja R. Ocena mozliwości wczesnej diagnostyki raka jajnika na podstawie oznaczeń wybranych białek surowicy. Ginekol Pol 2008; 79: 271-75.
49. Chang PL, Harkins L, Hsieh Yh. Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem 2008; 56: 57-66.
50. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008; 122: 889-97.
51. Mason CK, McFarlane S, Johnston PG. Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Cancer Ther 2008; 7: 548-58.